Drug intelligence / Profile preview

lutetium-177-catalase

Development stage: Phase 1
Lead developer: Peking University Cancer Hospital & Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intratumoral

Overview

Lutetium-177-catalase is a radiopharmaceutical that combines the enzyme catalase with the radioactive isotope lutetium-177. It is designed for tumor radionuclide therapy and is administered via intratumoral injection. The drug is currently being investigated in early phase clinical trials for advanced cancer treatment. The radioactive component, lutetium-177, emits beta radiation that can damage and destroy tumor cells while causing minimal damage to surrounding healthy tissue due to its controlled radiation delivery properties.

Other names: [Lu-177]-Catalase

Targets

Neuraminidase

Beyond the preview

Go deeper on lutetium-177-catalase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lutetium-177-catalase.

Explore the full profile